As Medical Pc

CLIA Laboratory Citation Details

3
Total Citations
38
Total Deficiencyies
19
Unique D-Tags
CMS Certification Number 33D2047877
Address 2493 Richmond Rd Suite 2, Staten Island, NY, 10306
City Staten Island
State NY
Zip Code10306
Phone(718) 227-5505

Citation History (3 surveys)

Survey - December 15, 2022

Survey Type: Special

Survey Event ID: 4J3911

Deficiency Tags: D2096 D2097 D6000 D6016 D2016 D2096 D2097 D6000 D6016

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a proficiency testing ( PT) desk review of the Center for Medicare and Medicaid Services (CMS) PT reports and PT records from the College of American Pathologists (CAP) PT program, the laboratory failed to participate and perform successfully in a PT program, approved by CMS, for the test analyte Aspartate Aminotransferase (AST) The following scores were assigned: 2022 first event = 0% (failure to participate) 2022 third event = 20% This is considered unsuccessful PT performance. Refer to D2097 D2096 ROUTINE CHEMISTRY Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a PT desk review of the CMS PT reports and PT records from the CAP PT program, the laboratory failed to participate and perform successfully in a PT program, approved by CMS, for the test analyte Total Calicium (T. Ca.) The following scores were assigned: 2022 third event = 60% This is considered unsatisfactory PT performance. D2097 ROUTINE CHEMISTRY CFR(s): 493.841(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a PT desk review of the CMS PT reports and PT records from the CAP PT program, the laboratory failed to participate and perform successfully in a PT program, approved by CMS, for the test analyte AST The following scores were assigned: 2022 first event = 0% (failure to participate) 2022 third event = 20% This is considered unsuccessful PT performance. Refer to D2097 D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on PT desk review of the PT CMS data reports and CAP PT program records, the laboratory director failed to fulfill the laboratory director's responsibilities and ensure that the laboratory achieved a satisfactory performance and successfully participate in a PT program, for the test analyte's AST and T. Ca. Refer to D6016. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; -- 2 of 3 -- This STANDARD is not met as evidenced by: Based on PT desk review of the PT CMS data reports and CAP PT program records, the laboratory director failed to fulfill the laboratory director's responsibilities and ensure that the laboratory achieved a satisfactory performance and successfully participate in a PT program, for the test analyte's AST and T. Ca. The following scores were assigned: AST 2022 first event = 0% (failure to participate) 2022 third event = 20% This is considered unsuccessful PT performance. T. Ca. 2022 third event = 60% This is considered unsatisfactory PT performance. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - July 14, 2021

Survey Type: Standard

Survey Event ID: EP5W11

Deficiency Tags: D5032 D5291 D5473 D5601 D5631 D5631 D5633 D5217 D5217 D5291 D5473 D5601 D5633 D5637 D5637 D5645 D5647 D6079 D6093 D6094 D5645 D5647 D6079 D6093 D6094

Summary:

Summary Statement of Deficiencies D5032 CYTOLOGY CFR(s): 493.1221 If the laboratory provides services in the subspecialty of Cytology, the laboratory must meet the requirements specified in 493.1230 through 493.1256, 493.1274, and 493.1281 through 493.1299. This CONDITION is not met as evidenced by: Based on surveyor's review of laboratory policies and procedures, laboratory records and confirmed in an interview with the pathologist/laboratory director, the laboratory failed to establish, reassess and document a workload limit for the laboratory director /technical supervisor (refer to D5633, D5637, D5645 and D5647);the pathologist failed to perform and document the quality control (QC) acceptability of the Hematoxylin and Eosin (H & E) and immunostain stain used for histopathology slides (refer to D5437, D5601). The cumulative effect of these systemic problems resulted in the laboratory's inability to ensure the accuracy and reliability of patient test results in the subspecialty of Cytology. D5217 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1) At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. This STANDARD is not met as evidenced by: Based on surveyor's review of the twice year verification records for histology and cytology slides and an interview with the pathologist/laboratory director/technical supervisor, the laboratory failed to verify the accuracy for the urine cytology slides and the Fluorescence In Situ Hybridization (FISH) images from August 3, 2020 Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 6 -- through July, 5, 2021. FINDINGS: The pathologist/laboratory director/technical supervisor confirmed on July 14, 2021 at approximately 12:30 PM that the laboratory failed to verify the accuracy for the urine cytology slides and the FISH images from August 3, 2020 through July 5, 2021. a. Approximately 150 patients were tested and reported for urine cytology. b. Approximately 50 patients were tested and reported for FISH. D5291 GENERAL LABORATORY SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1239(a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and, when indicated, correct problems identified in the general laboratory systems requirements specified at 493.1231 through 493.1236. This STANDARD is not met as evidenced by: Based on surveyor's review of the laboratory's Quality Assessment (QA) policy, lack of QA review records for the calendar year 2020 and an interview with the pathologist /laboratory director/technical supervisor, the laboratory failed to follow their established QA policy for an ongoing mechanism to monitor, assess and correct problems identified in the general laboratory systems. FINDINGS: 1. The pathologist /laboratory director/technical supervisor confirmed on July 14, 2021 at approximately 1:15 PM, that the laboratory failed to follow their established QA policy for an ongoing mechanism to monitor, assess and correct problems identified in the general laboratory systems. 2. The laboratory's QA policy requires an annual review of all phases of laboratory's histology and cytology testing. a. the laboratory failed to perform and document the QA review for the calendar year 2020. 3. The laboratory failed to identify and take

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - August 2, 2018

Survey Type: Standard

Survey Event ID: XIFT11

Deficiency Tags: D5629 D5637 D5629 D5637

Summary:

Summary Statement of Deficiencies D5629 CYTOLOGY CFR(s): 493.1274(c)(5) (c) Control procedures. The laboratory must establish and follow written policies and procedures for a program designed to detect errors in the performance of cytologic examinations and the reporting of results. The program must include the following: (c) (5) An annual statistical laboratory evaluation of the number of - (c)(5)(i) Cytology cases examined; (c)(5)(ii) Specimens processed by specimen type; (c)(5)(iii) Patient cases reported by diagnosis (including the number reported as unsatisfactory for diagnostic interpretation); (c)(5)(iv) Gynecologic cases with a diagnosis of HSIL, adenocarcinoma, or other malignant neoplasm for which histology results were available for comparison; (c)(5)(v) Gynecologic cases where cytology and histology are discrepant; and (c)(5)(vi) Gynecologic cases where any rescreen of a normal or negative specimen results in reclassification as low-grade squamous intraepithelial lesion (LSIL), HSIL, adenocarcinoma, or other malignant neoplasms. This STANDARD is not met as evidenced by: Based on surveyor's review of the cytology procedure manual and interview with the pathologist/laboratory director, the laboratory failed to follow their established policies and procedures for a program to evaluate and compare the laboratory statistics annually to detect errors in the performance of cytological examinations and reporting results. FINDINGS: The pathologist/laboratory director confirmed on August 2, 2018 at approximately 10:00 AM, that the laboratory failed to follow their establish policies and procedures for a program designed to detect errors in the performance of cytological examinations and the reporting of results annually for the calendar year 2017. D5637 CYTOLOGY CFR(s): 493.1274(d)(1)(ii) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- (d) Workload limits. The laboratory must establish and follow written policies and procedures that ensure the following: (d)(1)(ii) Each individual's workload limit is reassessed at least every 6 months and adjusted when necessary. This STANDARD is not met as evidenced by: Based on surveyor's review of the laboratory's cytology procedure manual, laboratory records and confirmed in an interview with the pathologist/laboratory director /technical supervisor, the laboratory failed to follow their established policies and procedures to ensure that workload limits would be reassessed at least every 6 months and adjusted when necessary for the pathologist who performs the primary screening of non-gynecologic cytology slides. FINDINGS: The pathologist/laboratory director /technical supervisor, confirmed on August 2, 2018 at approximately 10:30 AM, that the laboratory failed to follow their established policies and procedures to ensure that workload limits would be reassessed at least every 6 months and adjusted when necessary for the pathologist who performs the primary screening of non-gynecologic cytology slides. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access